Vertex Signs an Access Agreement with Scottish Government for Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor)

 Vertex Signs an Access Agreement with Scottish Government for Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor)

Vertex Enters into an Access Agreement with Scottish Government for Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor)

Shots:

  • The access agreement allows patients with eligible cystic fibrosis to access Orkambi and Symkevi (tezacaftor/ivacaftor) in combination with ivacaftor in Scotland
  • Vertex will collect real-world data on the combination therapies which will support future regulatory submission to the Scottish Medicines Consortium (SMC) following the 5yrs. access agreement
  • Orkambi is a combination therapy used to treat people with CF who have two copies of the F508del mutation. Symkevi is a combination regimen for the treatment of patients with CF aged ≥12yrs. who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation with CFTR gene mutation

 Click here to­ read full press release/ article | Ref: Vertex | Image: Vertex

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post